Stocks On My Screen For Week Starting March 1st, 2021

Every week, our model comes up with 40 stocks, 20 positive and 20 negatives, to watch for next week’s trading. The model is based on a mix of fundamental and quantitative factors, built on my proprietary database of detailed earnings model on more than 1375 U.S. listed companies. The historical data for these earnings models is sourced from SEC filings. Performance of last week’s model portfolio for the week was, Net: -3.3% Longs: -9.4% Shorts:  6.1% Assuming 5% is dedicated to each position, resulting in 0% net exposure and no…

Read More

Stocks On My Screen For Week Starting December 7th, 2020

Every week, our model comes up with 40 stocks, 20 positive and 20 negatives, to watch for next week’s trading. The model is based on a mix of fundamental and quantitative factors, built on my proprietary database of detailed earnings model on more than 1275 U.S. listed companies. The historical data for these earnings models is sourced from SEC filings. Performance of last week’s model portfolio for the week was, Net: 2.9% Longs: 2.5% Shorts:  0.4% Assuming 5% is dedicated to each position, resulting in 0% net exposure and no…

Read More

Fulgent Genetics Is Shining Brightly Again

As we have mentioned many times before, our circle of competence is limited in the healthcare industry and that’s why we have very few healthcare names in our database, but Fulgent Genetics (Nasdaq: FLGT) is there and it is shining brightly (no pun intended).  To overcome our shortcomings, we analyzed Fulgent Genetics like any other business rather than a medical test company, i.e. the company is good if it sells more, reduces the cost to manufacture, and repeats the process faster than its competitors. On those simple metrics, we are…

Read More